Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | LPL | P06858 | 3/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19184946 | 0.76 | MAPK1 (0.42) | MAPK1P2RX7 | |
| SCHEMBL1586037 | 0.72 | MAPK1 (0.67) | MAPK1P2RX7LPLLIPG | |
| SCHEMBL17256462 | 0.72 | P2RX7 (0.50) | MAPK1P2RX7LPLLIPG | |
| SCHEMBL31472207 | 0.69 | P2RX7 (0.47) | MAPK1P2RX7LPLLIPG | |
| SCHEMBL24366945 | 0.69 | P2RX7 (0.56) | MAPK1P2RX7LPLLIPG | |
| SCHEMBL30965873 | 0.69 | P2RX7 (0.47) | MAPK1P2RX7LPLLIPG | |
| SCHEMBL67926 | 0.69 | MAPK1 (1.00) | MAPK1P2RX7LPLLIPG | |
| SCHEMBL3655929 | 0.69 | P2RX7 (0.47) | MAPK1P2RX7LPLLIPG | |
| SCHEMBL30965858 | 0.69 | P2RX7 (0.80) | MAPK1P2RX7LPLLIPG | |
| SCHEMBL31136723 | 0.68 | MAPK1 (0.43) | MAPK1P2RX7LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138998-A1 | GLP-1 RECEPTOR AGONISTS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260125366-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12617783-B2 | Heterocyclic GLP-1R agonists | BIOMEA FUSION, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20250304572-A1 | HETEROCYCLIC GLP-1R AGONISTS | BIOMEA FUSION, INC. | 2025-10-02 | — | — | US | disclosed |
| EP-4598919-A1 | METHODS FOR TREATING CANCER | Scorpion Therapeutics, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| CN-120192324-A | Heterocyclic compound, pharmaceutical composition and application | 上海医药集团股份有限公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-119948034-A | Novel peptide-based nitrile compound and application thereof | 上海壹迪生物技术有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20250101021-A1 | METHODS OF MAKING TOLEBRUTINIB | PRINCIPIA BIOPHARMA INC. (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2024208225-A1 | DIHYDROTHIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海壹迪生物技术有限公司 | 2024-10-10 | — | — | WO | disclosed |
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| WO-2011143365-A1 | NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143365-A1 | NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011115938-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | AMGEN INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| EP-2328903-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2010030954-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304572-A1 | HETEROCYCLIC GLP-1R AGONISTS | GLP1R, GPR119, GIPR | MAPK1 816/4885P2RX7 124/4885LPL 43/4885 |
| US-12617783-B2 | Heterocyclic GLP-1R agonists | GLP1R, GIPR, GPR119 | MAPK1 1599/4885P2RX7 48/4885LPL 73/4885 |
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | GLP1R, GIPR, SLC5A1 | MAPK1 328/4885P2RX7 189/4885LPL 1514/4885 |
| US-20260138998-A1 | GLP-1 RECEPTOR AGONISTS AND METHODS OF USE | GLP1R, GIPR, GPR119 | MAPK1 1154/4885P2RX7 202/4885LPL 895/4885 |
| US-20250101021-A1 | METHODS OF MAKING TOLEBRUTINIB | ABL1, JAK2, JAK1 | MAPK1 205/4885P2RX7 1867/4885LPL 3933/4885 |
| US-20260125366-A1 | METHODS FOR TREATING CANCER | AKT2, AKT3, PIK3R5 | MAPK1 141/4885P2RX7 644/4885LPL 1438/4885 |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | MAPK1 3616/4885P2RX7 1520/4885LPL 1651/4885 |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | MAPK1 3186/4885P2RX7 2223/4885LPL 1228/4885 |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | MAPK1 1417/4885P2RX7 3722/4885LPL 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.